AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2217
-0.0052 (-2.29%)
Sep 11, 2026, 4:00 PM EDT - Market closed
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $26.00K in the quarter ending June 30, 2026, with 4.00% growth. This brings the company's revenue in the last twelve months to $95.00K, down -21.49% year-over-year. In the year 2025, AIM ImmunoTech had annual revenue of $88.00K, down -48.24%.
Revenue (ttm)
$95.00K
Revenue Growth
-21.49%
P/S Ratio
71.04
Revenue / Employee
$4,524
Employees
21
Market Cap
6.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.00K | -82.00K | -48.24% |
| Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
| Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
| Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
| Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
| Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
| Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
| Dec 31, 2018 | 367.00K | -70.00K | -16.02% |
| Dec 31, 2017 | 437.00K | 345.00K | 375.00% |
| Dec 31, 2016 | 92.00K | -41.00K | -30.83% |
| Dec 31, 2015 | 133.00K | -64.00K | -32.49% |
| Dec 31, 2014 | 197.00K | 47.00K | 31.33% |
| Dec 31, 2013 | 150.00K | -63.00K | -29.58% |
| Dec 31, 2012 | 213.00K | 52.00K | 32.30% |
| Dec 31, 2011 | 161.00K | 26.00K | 19.26% |
| Dec 31, 2010 | 135.00K | 24.00K | 21.62% |
| Dec 31, 2009 | 111.00K | -154.00K | -58.11% |
| Dec 31, 2008 | 265.00K | -794.00K | -74.98% |
| Dec 31, 2007 | 1.06M | 126.00K | 13.50% |
| Dec 31, 2006 | 933.00K | -150.00K | -13.85% |
| Dec 31, 2005 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 4.70M |
| Evogene | 1.66M |
| CollPlant Biotechnologies | 389.00K |
| Lexaria Bioscience | 194.00K |
| Cardio Diagnostics Holdings | 14.45K |
| Creative Medical Technology Holdings | 3.00K |
| Ernexa Therapeutics | 1.00K |
AIM News
- 4 days ago - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - GlobeNewsWire
- 11 days ago - AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - GlobeNewsWire
- 13 days ago - AIM ImmunoTech granted patent for Ampligen - TheFly
- 13 days ago - AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - GlobeNewsWire
- 17 days ago - AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Quarterly report: Q2 2026 - Filings
- 5 weeks ago - AIM ImmunoTech Earnings release: Q2 2026 - Filings